ABSTRACT Objective: This study was performed to quantify adherence rates to lipid-lowering drug therapy among members of the Canadian Forces (CF) and to identify factors associated with nonadherence. Methods: Pharmacy claims were reviewed for all CF members who received a lipid-lowering drug between April I and June 1, 2003. Subjects were categorized as adherent if records indicated consumption of at least 80% of prescribed doses. Logistic regression was performed to assess the impact of patient and drug characteristics upon adherence. Results: Overall adherence rate at I year was 38.5% among all users of lipid-lowering medications. Adherence did not vary among the different classes of lipid-lowering drugs. Duration of service was the only independent predict9r of adherence. Conclusions: Despite a relative lack of treatment barriers and the presence of established treatment programs in the CF health care system, long-term adherence with lipid-lowering medications remains suboptimal in this population.
INTRODUCTION
Lipid-lowering therapy, particularly with 3-hydroxy-J=methyl-"', glutaryl-coenzyme A reductase inhibitors (statins), has been proven to reduce cardiovascular morbidity and mortality.1-3 However, sustained use of such medications is required to achieve these benefits. Two major studies have indicated that long-term adherence to lipid-lowering drug therapy is low among elderly patients, with less than a third of prescriptions continuing to be taken 1 year after initiation of therapy. 4, 5 Adherence is similarly poor even among high-risk patients with established cardiovascular disease.5,6This gap in treatment represents a lost opportunity to reduce morbidity and mortality due to cardiovascular disease.
In the Canadian Forces (CF), significant expenditures are associated with lipid-lowering medications, which are continuously among the most common and most costly classes of medication prescribed for our members. A previous study performed in our population demonstrated that screening for dyslipidemia is very comprehensive, with almost all serving members screened irrespective of their baseline risk for cardiovascular disease.? However, this study also documented that, for a significant proportion of our members, control of their dyslipidemiawas suboptimaI.7 r Our department (Directorate of Medical Policy, Pharmacy Policies and Standards) has also evaluated the impact of two different initiatives upon dyslipidemia control, both of which relied primarily upon pharmacist interventions. In the first initiative, selection of three preferred statins for inclusion on our benefit list provided an opportunity for our pharmacists to discuss optimal doses of statins during therapeutic substitution.8In the second initiative, pharmacists at three specific CF practice sites provided more intensive counseling and follow-up to patients referred by their primary care physician. 9 Both of these initiatives demonstrated improvement in dyslipidemia profiles for patients who were subject to pharmacists' interventions. Our organization has thus invested and continues to dedicate a significant amount of resources to the identification and management of dyslipidemia.
Despite the success demonstrated with these efforts, however, we recognized that not all CF members would be able to access or otherwise receive intensive counseling and follow-up from pharmacists or other health care providers, due to the constraints inherent in oui health care system. Because our younger, relatively disease-free population stands to benefit substantially from lipid-lowering therapy, we were interested to know whether our previous initiatives, coupled with increasing awareness of the importance of dyslipidemia management, were associated with greater adherence to lipidlowering therapy overall in CF members.
OBJECTIVES
The primaryobjectivefor this study was to quantify adher- 
METHODS

Study Design
A cohort study was perfonned using infonnation from two phannacy databases: one containing prescriptions dispensed from military phannacies and another containing prescriptions. obtained by CF members from civilian phannacies. These two databases were merged into a single file which was subsequently blinded for analysis. The study protocol was submitted to and received approval from the Ottawa Hospital Research Ethics Board before its execution.
Study Population
Male and female Regular Forces CF members who received a lipid-lowering agent between the dates of April I, 2003 and June 1, 2003 were eligible for inclusion in this study. Patients who had <3 months of follow-up infonnation related to prescription drug use were excluded from the study.
Data Collection
For each eligible patient, infonnation was collected on patient demographics-age, sex, rank Uunior or senior noncommissioned member [NCM] vs. junior or senior officer), service element (air, land, sea), duration of service, and geographic location by military base/wing-and medication use (drug, dose, date(s) of prescriptions, and quantities dispensed).
Data Analysis
Adherence rates were calculated based on the method previously described by Jackevicius.5 Prescriptions for lipid-lowering medications were assessed for 1 year following the index prescription. Patients were deemed adherent if their use of lipid-lowering medication(s) was sustained during 12 consecutive months. Sustained use was defined based on the pattern of refills obtained: for each prescription, actual refill dates were compared to expected refill date~that were identified based on the dose prescribed and quantity dispensed, allowing a 20% grace period for late refills. Patients were required to refill all prescriptions for specific lipid-lowering medications within the expected "windows" during a 12-month period to be deemed adherent. The X2test statistic was then used to examine differences between adherent and nonadherent members for different drug classes (with combination therapy excluded from this analysis.). Stepwise multivariate analysis was used to identify factors independently associated with nonadherence.
RESULTS
A total of 1,360 members was included in the cohort. As expected in a military population, the members were predominantly male (97% of study subjects); this proportion was MILITARY MEDICINE, Vol. 173, July 2008 ---7 higher than among the overall CF population, where~85% of CF members are male. Consistent with the disease state being evaluated, the mean age in this cohort was higher than the general CF population (44.6 years, range 24-61 years, com:" pared to 36 yearsin the CF overall).Durationof servicereflected the age of subjects, averaging 23.4 years (range, 1-38 years). The majority of cohort members were senior NCMs (49%~.
The overall I-year adherence rate for all lipid-lowering medications was 38.5%. Nonadherent members were younger, had fewer years of service, and were less likely to be senior NCMs (Table I ). There were no significant differences in adherence between members taking different classes of lipidlowering medications (Fig. 1) . Due to variability in the numbers of eligible members located at different military sites (ranging from 1 to 257 at 30 distinct sites), no significant differences were found in adherence rates among the CF bases (range, 14.3-100%, data not shown).
Medication class was not significantly associated with nonadherence (p < 0.15) in univariate analysis, and was thus excluded from the multivariate analysis. Univariate analysis identified age and duration of employment to be significant predictors of adherence (Table II) , however, duration of service was the only remaining variable which was independently associated with nonadherence in multivariate analysis (data not shown).
DISCUSSION
Our results, although disappointing, are not entirely unexpected. Medication taking is a complex behavior, with many 667 opportunities for mishap. Many contributing factors to nonadherence have been identified previously in diverse patient populations, both with regard to medications and other therapeutic interventions.1OFactors influencing adherence include both patient-specific elements, such as attitudes toward illness and medication taking, !l.12as well as characteristics unique to the diseasel3-15and medication regimensl3 (including complexity of dosing, number of medications, and side effects). In our population, many factors which have been shown or hypothesized to contribute to nonadherence (e.g., illiteracy, prohibitive drug acquisition costs) are lower or absent. Nevertheless, our study has found that levels of adherence to lipid-lowering medication~e equally poor in Canadian military personnel as among other populations studied to date.
In contrast to other studies, our research also sought to determine whether adherence was similar among different 668 --~~~c lasses of lipid-lowering medications. We had hypothesized that, given greater awareness and concerns regarding the side effects of statins-with one agent (cerivastatin) recently withdrawn from the market due to an increased risk of rhabdomyolysisl6-other lipid-lowering agents may have been used preferentially in managing dyslipidemia among our members. Our results indicate, however, that statins remain by far the most commonly prescribed lipid-lowering agents, although a notable number of our members are managed with other agents either alone or in combination with a statin. Adherence rates were not shown to vary with drug class, although our statistical power to detect such a difference was likely limited due to the small numbers of individuals taking non-statin lipid-lowering agents alone.
Our study, like those of other authors, is also limited by the quality of information in our pharmacy claims database. Although such databases are an invaluable source of information on large groups, such information may not be complete. Most notably, we cannot estimate the number of prescriptions for lipid-lowering medications which were never filled at the outset. We also cannot determine whether all doses dispensed were indeed taken and taken appropriately, a point of importance given that certain statins are more effective when administered in the evening. Our results may thus underestimate the true rates of nonadherence in our population. However, these limitations are also present in other studies of this design and thus allow for a comparable analysis of our performance to other populations.
Despite its limitations, our study does suggest some specific opportunities for improving management of dyslipidemia in CF members. Most importantly, despite the positive impact associated with previous pharmacy-centered interventions, such efforts alone are obviously not sufficient to ensure consistent and sustained uptake of lipid-lowering therapy over the longer term on a population-wide basis. This is particularly true in the present age, when extreme shortages of pharma~ists and other primary health care providers-and competing demands on such personnelmay not allow them to devote sufficient resources to manage complex disease states such as dyslipidemia. Additionally, the management of dyslipidemia has been evolving at a rapid pace, with new guidelines and more aggressive treatment goals introduced on a frequent basis. This further challenges practitioners attempting to remain up-to-date on the most appropriate management strategies, let alone communicate the importance of these to their patients in a consistent manner. , The disappointing results of our current study, when viewed in light of our extensive work thus far to promote judicious use of lipid-lowering medications, strongly suggest that future efforts to address this issue should perhaps be expanded to involve other health professionals in a structured manner. Our previous review of activities undertaken by pharmacists at lipid clinics revealed that many of the profes- sional interventions included referrals to other health care providers (predominantly dieticians), and general recommendations to increase physical activity levels.9 Given that diet and exercise also have positive influences upon lipid levels and cardiovascular health outcomes, health care professionals who are trained to address these elements should also be involved in the standard management of members with dyslipidemia. This approach is also in accordance with many recent Canadian guidelines for management of diabetes and other conditions associated with dyslipidemia. 17, 18 Our results alsoLsuggestthat our lipid clinic programs may do well to embrace a more comprehensive focus on cardiovascular health, or overall health in general, rather than focusing primarily upon control of dyslipidemia. Presently, entry into the lipid clinic program requires initial referral from the primary care physician; the program will thus selectively target those members with established dyslipidemia, as well as those who have failed to respond to usual treatment. However, many members may not perceive adequate benefit from the multiple labor-intensive interventions (involving diet, exercise, drug therapy, laboratory monitoring, and physician follow-up) required to adequately manage lipid abnormalities alone, thus contributing to noncompliance in the long-term. A relatively isolated focus upon dyslipidemia management may also not be warranted, given the increasing body of evidence implicating dyslipidemia as a factor in more complex disease states such as metabolic syndrome.19In-stead, programs which focus on improving overall cardiovascular health may be better received by military members, as these would focus on both short-term and long-term benefits together. Immediate improvements in exercise tolerance and general feelings of well-being can often result from established cardiovascular risk reduction strategies, such as smoking cessation, weight loss, and structured exercise regimens, and may also be associated with greater long-term adherence to treatment.2O:21 By focusing on these interventions in place of dyslipidemia-specific targets, we may achieve better longterm treatment adherence and improved health outcomes in the future.
CONCLUSIONS
An extensive review of our pharmacy claims database revealed that adherence to lipid-lowering therapy was suboptimal among members of the Canadian Forces. Consistent with reports in civilian populations, adherence rates at 1 year following initiation of lipid-lowering therapy were -40% overall. Adherence was independently associated with duration of military service, perhaps reflecting the greater perceived importance of reducing cardiovasc,ular risk through medication-taking behavior among older members. Future efforts to manage dyslipidemia on a more widespread basis should involve multidisciplinary health care teams, and could perhaps be tailored to address overall cardiovascular health MILITARY MEDICINE, Vol. 173, July 2008 and associated short-term benefits, such as improved exercise tolerance and weight loss, as opposed to focusing upon lipid levels alone.
